secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-05-16T23:59:59+00:00
Accession:  0001193125-24-140688
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure
--------------------------------------------------------------------------------

- Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.
- Cunningham is a consultant from Danforth Advisors, providing CFO services at an hourly rate under consulting agreement.
- Cunningham, age 62, CPA, has served as CFO for Bionomics Limited and other biotech firms; no family relationships with executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/0001193125-24-140688-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524140688/d841479d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-140688

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer